VIDEO: Advances in CAR T-cell manufacturing, real-world data highlighted at ASH

ByNikhil C. Munshi, MD

ByCory Perla

Fact checked byPatricia Nale, ELS

NEW ORLEANS — Making chimeric antigen receptor T cells quickly is going to become a reality, according to Nikhil C. Munshi, MD, who discusses presentations from the ASH Annual Meeting and Exposition in this video perspective.

Munshi focuses on presentations of real-world data validating CAR T-cell therapy responses, as well as advances in CAR T-cell therapy manufacturing.

In addition, Munshi discusses data on why some patients respond to CAR T-cell therapy and why some relapse.

"Stay tuned for more data on the markers of resistance, response and relapse, and based on that, we will come up with new CAR T-cell products,” he said.

References:

Berdeja J, et al. Abstract 364. Presented at: ASH Annual Meeting and Exposition; Dec. 10-13, 2022; New Orleans.
Costa LHM, et al. Abstract 566. Presented at: ASH Annual Meeting and Exposition; Dec. 10-13, 2022; New Orleans.
Richardson P, et al. Abstract 568. Presented at: ASH Annual Meeting and Exposition; Dec. 10-13, 2022; New Orleans.

Published by:

Sources/Disclosures

Collapse

Source:

Healio Interviews

Disclosures: Munshi reports serving on advisory boards or consulting for Adaptive, AbbVie, Amgen, BMS, Celgene, GSK, Janssen, Karyopharm, Legend, Novartis, OncoPep, Pfizer and Takeda, current equity holder in publicly traded company.

Take Homes in Multiple Myeloma

Read more

VIDEO: Advances in CAR T-cell manufacturing, real-world data highlighted at ASH

References:

Related Content